<SEC-DOCUMENT>0001104659-25-006734.txt : 20250128
<SEC-HEADER>0001104659-25-006734.hdr.sgml : 20250128
<ACCEPTANCE-DATETIME>20250128164409
ACCESSION NUMBER:		0001104659-25-006734
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250128
DATE AS OF CHANGE:		20250128

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Quoin Pharmaceuticals, Ltd.
		CENTRAL INDEX KEY:			0001671502
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89873
		FILM NUMBER:		25564918

	BUSINESS ADDRESS:	
		STREET 1:		23 HATA'AS STREET
		CITY:			KFAR SABA
		STATE:			L3
		ZIP:			44425
		BUSINESS PHONE:		97299741444

	MAIL ADDRESS:	
		STREET 1:		23 HATA'AS STREET
		CITY:			KFAR SABA
		STATE:			L3
		ZIP:			44425

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cellect Biotechnology Ltd.
		DATE OF NAME CHANGE:	20160721

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cellect Biomed Ltd.
		DATE OF NAME CHANGE:	20160406

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Myers Michael
		CENTRAL INDEX KEY:			0001959547
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		AZRIELI CENTER
		STREET 2:		ROUND TOWER, 30TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6701101
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001104659-25-000396</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Myers Michael -->
          <cik>0001959547</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Ordinary Shares, no par value per share (represented by American Depositary Shares)</securitiesClassTitle>
      <dateOfEvent>01/27/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001671502</issuerCIK>
        <issuerCUSIP>74907L300</issuerCUSIP>
        <issuerName>Quoin Pharmaceuticals Ltd.</issuerName>
        <address>
          <com:street1>42127 Pleasant Forest Court</com:street1>
          <com:city>Ashburn</com:city>
          <com:stateOrCountry>VA</com:stateOrCountry>
          <com:zipCode>20148-7349</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Dr. Michael Myers</personName>
          <personPhoneNum>703-980-4182</personPhoneNum>
          <personAddress>
            <com:street1>42127 Pleasant Forest Court</com:street1>
            <com:city>Ashburn</com:city>
            <com:stateOrCountry>VA</com:stateOrCountry>
            <com:zipCode>20148-7349</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001959547</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Michael Myers</reportingPersonName>
        <fundType>PF</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>939230.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>939230.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>939230.00</aggregateAmountOwned>
        <isAggregateExcludeShares>Y</isAggregateExcludeShares>
        <percentOfClass>4.9</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one Ordinary Share of the Issuer. Rows 7, 9 and 11 include (i) 602,808 ADSs held directly, (ii) 19,765 ADSs issuable within 60 days of the filing of this statement on Schedule 13D (this "Statement") upon the exercise of outstanding options, and (iii) 316,657 issuable upon the exercise of outstanding warrants. Excludes (i) 604,946 ADS issuable upon the exercise of outstanding options which are not exercisable within 60 days of this Statement , and (ii) 794,455 shares issuable pursuant to warrants which are not currently exercisable due to a 4.99 percent ownership blocker.

(2) Percentage calculated based on 18,485,830 Ordinary Shares outstanding as of January 27, 2025.

This Amendment No. 1 to Schedule 13D amends and supplements the previously filed Schedule 13D filed by Michael Myers (the "Reporting Person"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Ordinary Shares, no par value per share (represented by American Depositary Shares)</securityTitle>
        <issuerName>Quoin Pharmaceuticals Ltd.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>42127 Pleasant Forest Court</com:street1>
          <com:city>Ashburn</com:city>
          <com:stateOrCountry>VA</com:stateOrCountry>
          <com:zipCode>20148-7349</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item4>
        <transactionPurpose>The Ordinary Shares reported herein as beneficially owned by the Reporting Person were acquired by the Reporting Person for investment purposes.

As a result of the exercise of pre-funded warrants, Series F Warrants and Series G Warrants by other investors in the Company's December 2024 offering, the Company's outstanding Ordinary Shares (represented by ADSs) as of January 27, 2025 increased to 18,485,830. As a result of such exercises, the Reporting Person's beneficial ownership decreased to below 5% of the Company's outstanding Ordinary Shares (represented by ADSs).</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>The responses set forth in rows 11 through 13 and the related "Comments for Type of Reporting Person" on the cover page to this Statement are incorporated by reference into this Item 5.</percentageOfClassSecurities>
        <numberOfShares>The responses set forth in rows 7 through 10 and the related "Comments for Type of Reporting Person" on the cover page to this Statement are incorporated by reference into this Item 5.</numberOfShares>
        <transactionDesc>Except as reported in this Statement, the Reporting Person has not effected any transactions in the Issuer's securities within the past 60 days. On December 23, 2024, the Reporting Person purchased 555,556 ADSs together with 555,556 Series F Warrants to purchase up to 555,556 ADSs and 555,556 Series G Warrants to purchase up to 555,556 ADSs in the Issuer's public offering. Each ADS was purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS at a combined public offering price of $0.45. On December 9, 2024, the Issuer granted Dr. Myers an option to purchase 536,603 ADSs, which option is not exercisable within 60 days of the filing of this Statement.</transactionDesc>
        <listOfShareholders>No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Ordinary Shares beneficially owned by the Reporting Person.</listOfShareholders>
        <date5PercentOwnership>State the date on which the reporting person ceased to be the beneficial owner of more than five percent of the class of securities: January 27, 2025</date5PercentOwnership>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Michael Myers</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Michael Myers</signature>
          <title>Dr. Michael Myers</title>
          <date>01/28/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
